سعر ليكفيو 284مجم/1.5مل سرنجة معبأة 2024

Leqvio inclisiran 284 mg/1.5 ml solution for subcutaneous injection, one prefilled syringe (Novartis); small interfering RNA that lowers LDL cholesterol.

• Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolaemia.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet and exercise to reduce LDL-C in adults and paediatric patients 12 years and older with heterozygous familial hypercholesterolaemia (HeFH), and in paediatric patients 12 years and older with homozygous FH (HoFH).Population: Adults and adolescents 12 years and olderDailyMed (U.S. National Library of Medicine)

• Adverse reactions in at least 3% of adults and more often than placebo: injection site reaction (8% vs 2%), arthralgia (5% vs 4%), bronchitis (4% vs 3%).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Post-marketing: anaphylaxis, angioedema, rash, pruritus and urticaria.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Prior serious hypersensitivity reaction to inclisiran or any excipient (reactions have included anaphylaxis and angioedema).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity reactions including anaphylaxis and angioedema have been reported; advise patients to seek prompt medical attention.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognised, or consider the ongoing therapeutic needs of the patient; may cause fetal harm based on its mechanism of action; treatment of hypercholesterolaemia is generally not necessary during pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk; present in rat milk; poor oral bioavailability of oligonucleotides makes adverse infant effects unlikely; weigh benefits of breastfeeding against the mother's need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Inclisiran: GalNAc-conjugated siRNA taken up by hepatocytes; directs catalytic breakdown of PCSK9 mRNA, increasing LDL receptor recycling and expression and lowering circulating LDL-C (US label 12.1).